current and future therapies for pv: ropeginterferon alfa-2b
Published 4 years ago • 1.6K plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
3:00
ropeginterferon alpha-2b as an effective treatment against pv
-
1:29
ropeginterferon alfa-2b for polycythemia vera: impacts and considerations
-
3:15
updates on ropeginterferon in pv
-
1:39
upcoming agents in et and pv
-
2:55
pv-aim: using machine learning to predict resistance to hydroxyurea therapy in patients with pv
-
3:29
current approaches and new approvals in mf and pv
-
2:14
risk-adapted treatment of et & pv
-
1:25
the current approach to managing patients with prefibrotic pmf
-
1:28
surpass et: ropeginterferon alfa-2b vs anagrelide for second-line essential thrombocythemia
-
2:14
the role of bmt & clinical trials in patients with pv with multiple treatment-limiting toxicities
-
1:01
the current landscape of antibody-based therapies in r/r dlbcl
-
5:17
determining the potential of ropeginterferon alfa-2b in polycythemia vera
-
1:11
exciting updates in all and the value of novel immunotherapies
-
7:22
escrs 2023 - clinical outcomes with a new generation hydrophobic trifocal iol
-
2:02
future of precision medicine 2023
-
3:14
targeted therapy for type 2 diabetes
-
1:17
what is your vision for the future of healthcare? | roche
-
2:12
novel agents of interest for the treatment of bpdcn
-
1:53
the current immunotherapeutic landscape for treatment of dlbcl